<DOC>
	<DOCNO>NCT02271113</DOCNO>
	<brief_summary>In study , investigator evaluate safety , pharmacokinetics effect target biomarkers coagulation , cell adhesion , leukocyte platelet activation GMI-1271 , E-selectin antagonist , healthy volunteer .</brief_summary>
	<brief_title>Phase I Study Assess Safety Pharmacokinetics GMI-1271 Healthy Adult Subjects</brief_title>
	<detailed_description>Investigators evaluate single ascend dose ( SAD ) multiple ascend dose ( MAD ) fashion , safety , pharmacokinetics effect target biomarkers coagulation , cell adhesion , leukocyte platelet activation GMI-1271 , E-selectin antagonist , healthy volunteer .</detailed_description>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Age 1875 year Male female Medically healthy , defined absence clinically significant screen result ( e.g . laboratory profile , medical history , electrocardiogram ( ECG ) , physical examination ) BMI 1835 kg/m2 Voluntary consent participate study No evidence Lower Extremity Deep Vein Thrombosis ( LE DVT ) baseline ultrasound Use prescription , investigational , herbal , supplemental , counter medication include aspirin within 14 day ( SAD phase ) 7 day ( MAD phase ) prior day 1 unwilling/unable refrain use medication day 18 SAD phase day 112 MAD phase study Previous administration GMI1271 Positive drug test screen baseline positive alcohol test baseline unwilling/unable refrain use drug alcohol day 18 SAD phase day 112 MAD phase study Pregnant breastfeed Unwilling unable use contraception time participation trial 14 day afterwards ( sexual abstinence permissible ) Positive HIV , Hepatitis B surface antigen Hepatitis C antibody screen Hypersensitivity allergic reaction compound related GMI1271 Use moderate caffeine ( â‰¥ 300 mg/day ) within 48 hour prior dose ( day 1 ) History bleed disorder Any liver function test &gt; 1.5 time upper limit normal renal insufficiency creatinine clearance &lt; 30 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>